Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Evolution ARCALYST revenue growth of 62% for full-year 2025 was primarily driven by the expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment immediately following NSAID and colchicine failure. Management attributes commercial success to a fundamental shift in the treatment paradigm, supported by the 2025 ACC clinical guidance which ratified IL-1 inhibition as a preferred second-line approach. The company is leveraging its profitable ARCALYST franchise to fund strategic investments in digital marketing, AI-driven physician targeting, and the development of internally discovered assets. Operational focus has shifted toward 'unlocking the next phase of growth' by increasing penetration in the multiple recurrence market and expanding earlier into the first recurrence population. Strategic positioning in the recurrent pericarditis market is being reinf
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals International (KNSA) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wells Fargo & Company from $50.00 to $53.00. They now have an "overweight" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wedbush from $50.00 to $53.00. They now have an "outperform" rating on the stock.MarketBeat
KNSA
Earnings
- 2/24/26 - Miss
KNSA
Sec Filings
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- 2/24/26 - Form S-8
- KNSA's page on the SEC website